carnitine has been researched along with Hepatitis C in 5 studies
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study prospectively evaluated the preventative efficacy of L-carnitine supplementation against hemolytic anemia during antiviral treatment using ribavirin in patients with hepatitis C virus (HCV)-related chronic liver disease." | 7.91 | Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection. ( Akahane, T; Furukawa, M; Kaji, K; Kawaratani, H; Kitade, M; Kitagawa, K; Mitoro, A; Moriya, K; Namisaki, T; Okura, Y; Saikawa, S; Sato, S; Sawada, Y; Seki, K; Shimozato, N; Takaya, H; Yamao, J; Yoshiji, H, 2019) |
| " Group 1, composed of 25 patients, was treated with leucocytic IFN-alpha at a dosage of 3 million IU thrice a week; group 2 (25 patients) was treated with the same protocol as group 1, but was also administered carnitine 2 g per os daily." | 6.71 | L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. ( Luca, S; Malaguarnera, M; Neri, S; Pennisi, G; Pistone, G; Saraceno, B, 2003) |
| " This study prospectively evaluated the preventative efficacy of L-carnitine supplementation against hemolytic anemia during antiviral treatment using ribavirin in patients with hepatitis C virus (HCV)-related chronic liver disease." | 3.91 | Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection. ( Akahane, T; Furukawa, M; Kaji, K; Kawaratani, H; Kitade, M; Kitagawa, K; Mitoro, A; Moriya, K; Namisaki, T; Okura, Y; Saikawa, S; Sato, S; Sawada, Y; Seki, K; Shimozato, N; Takaya, H; Yamao, J; Yoshiji, H, 2019) |
| " Group 1, composed of 25 patients, was treated with leucocytic IFN-alpha at a dosage of 3 million IU thrice a week; group 2 (25 patients) was treated with the same protocol as group 1, but was also administered carnitine 2 g per os daily." | 2.71 | L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. ( Luca, S; Malaguarnera, M; Neri, S; Pennisi, G; Pistone, G; Saraceno, B, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sato, S | 1 |
| Moriya, K | 1 |
| Furukawa, M | 1 |
| Saikawa, S | 1 |
| Namisaki, T | 1 |
| Kitade, M | 1 |
| Kawaratani, H | 1 |
| Kaji, K | 1 |
| Takaya, H | 1 |
| Shimozato, N | 1 |
| Sawada, Y | 1 |
| Seki, K | 1 |
| Kitagawa, K | 1 |
| Akahane, T | 1 |
| Mitoro, A | 1 |
| Okura, Y | 1 |
| Yamao, J | 1 |
| Yoshiji, H | 1 |
| Nakanishi, H | 1 |
| Kurosaki, M | 1 |
| Izumi, N | 1 |
| Elsemman, IE | 1 |
| Mardinoglu, A | 1 |
| Shoaie, S | 1 |
| Soliman, TH | 1 |
| Nielsen, J | 1 |
| Neri, S | 1 |
| Pistone, G | 1 |
| Saraceno, B | 1 |
| Pennisi, G | 1 |
| Luca, S | 1 |
| Malaguarnera, M | 1 |
| DaVanzo, WJ | 1 |
| Ullian, ME | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for carnitine and Hepatitis C
| Article | Year |
|---|---|
L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C.
Topics: Adult; Carnitine; Case-Control Studies; Chronic Disease; Drug Interactions; Fatigue; Female; Hepatit | 2003 |
4 other studies available for carnitine and Hepatitis C
| Article | Year |
|---|---|
Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.
Topics: Aged; Anemia, Hemolytic; Carnitine; Drug Therapy, Combination; Female; Hepatitis C; Humans; Male; Mi | 2019 |
[Antiviral effect of carnitine for chronic hepatitis or liver cirrhosis patients].
Topics: Antiviral Agents; Carnitine; Hepatitis B; Hepatitis C; Hepatitis, Chronic; Humans; Liver Cirrhosis | 2015 |
Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism.
Topics: Acyl Coenzyme A; Acyltransferases; Carcinoma, Hepatocellular; Carnitine; Chromosomes, Human, Pair 1; | 2016 |
L-carnitine administration reverses acute mental status changes in a chronic hemodialysis patient with hepatitis C infection.
Topics: Carnitine; Consciousness Disorders; Hepatitis C; Humans; Hyperammonemia; Male; Middle Aged; Renal Di | 2002 |